TP 3654 clinical trials
Also written TP-3654.
How each study uses TP 3654 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TP 3654 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TP-3654
- 4
Studies by the year they started
4 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test TP 3654.
- Apr 2027A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisPhase 1/2 · Sumitomo Pharma America, Inc.
Studies
Open first, then newest update. How each study uses TP 3654 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisRecruitingPhase 1/2Sumitomo Pharma America, Inc.NCT04176198Written as Nusivertib
- TP-3654 Food Effect StudyCompletedPhase 1Sumitomo Pharma America, Inc.NCT07492355Written as TP-3654
- Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654CompletedPhase 1Sumitomo Pharma America, Inc.NCT06389955Written as TP 3654
- Study of TP-3654 in Patients With Advanced Solid TumorsCompletedPhase 1Sumitomo Pharma America, Inc.NCT03715504Written as TP-3654
Codes
What other systems call TP 3654 · ClinicalTrials.gg INT004136
- MeSH (NLM) C117473TP 3654One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C117473 | TP 3654 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.